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REVIEW
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ABSTRACT
A deficiency in ADAMTS13 (A Disintegrin And Metalloprotease with ThromboSpondin type-1
repeats, member 13) is associated with thrombotic thrombocytopenic purpura (TTP). Congenital
TTP is caused by a defect in the ADAMTS13 gene resulting in decreased or absent enzyme activity;
acquired TTP results from autoantibodies that either inhibit the activity or increase the clearance
of ADAMTS13. Despite major progress in recent years in our understanding of the disease, many
aspects around the pathophysiology of TTP are still unclear. Newer studies expanded the TTP
field from ADAMTS13 and inhibitory antibodies to immune complexes, cloned autoantibodies,
and a possible involvement of other proteases. Additionally, several new treatment strategies
supplementing plasma-exchange and infusion are under investigation for a better and more
specific treatment of TTP patients. In this review, we discuss the recent insights in TTP patho-
physiology and describe upcoming therapeutic opportunities.
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Introduction
The multimeric glycoprotein von Willebrand factor
(VWF) plays an important role in maintaining normal
hemostasis by mediating platelet adhesion to collagen
during vascular injury.[1] Endothelial cells and platelets
secrete VWF as ultra-large (UL) multimers. As a conse-
quence of the shear conditions in the flowing blood,
these UL-VWF multimers unfold, thereby exposing their
cryptic platelet binding sites turning them into a
prothrombotic state. Under normal physiological
conditions, UL-VWF multimers are digested by the
metalloprotease ADAMTS13 (A Disintegrin And
Metalloprotease with ThromboSpondin type-1 repeats,
member 13) into smaller, folded, and quiescent multi-
mers. A deficiency in ADAMTS13 is associated with the
life-threatening microangiopathic disorder thrombotic
thrombocytopenic purpura (TTP), where during acute
episodes of TTP, VWF-rich platelet thrombi block the
microcirculation. Acute episodes of TTP are suspected
by thrombocytopenia and hemolytic anemia.[2]
Patients suffer from symptoms such as neurologic
abnormalities and organ failure, which without treat-
ment can have fatal consequences. The exact molecular
trigger for acute TTP episodes is not known; however,
disease onset is often related to pregnancy, infections,
or the use of certain drugs.[3]
ADAMTS13
ADAMTS13 is a multi-domain enzyme consisting of a
metalloprotease (M) and disintegrin-like (D) domain,
a thrombospondin type-1 repeat (T), a cysteine-rich (C)
and spacer (S) domain, seven additional thrombospon-
din type-1 repeats, and two CUB domains (visualized in
Figure 1). ADAMTS13 circulates as a constitutively active
enzyme; however, cleavage of its substrate only occurs
upon unfolding of VWF. Indeed, unfolding of the UL-
VWF multimers under normal shear conditions exposes
not only the platelet binding sites but also the cryptic
ADAMTS13 cleavage site, which is situated in the VWF
A2 domain. Upon unfolding of the A2 domain, the
proximal MDTCS domains of ADAMTS13 bind the cryp-
tic domains in VWF like a molecular zipper, thereby
positioning the proteolytically active metalloprotease
domain of ADAMTS13 toward the cleavage site at posi-
tion Tyr1605-Met1606 in VWF.[4] The role of the
remaining distal thrombospondin and CUB domains is
less clear. These distal domains were recently shown to
regulate the proteolytic activity of ADAMTS13 by shield-
ing the proximal domains.[5,6] The distal domains are
crucial for docking full-length ADAMTS13 onto VWF
under high shear conditions,[7] which results in
unshielding of the MDTCS domains and allosteric acti-
vation of ADAMTS13.[6] In line with this, C-terminally
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truncated ADAMTS13 showed reduced activity, result-
ing in faster thrombus formation in mice.[8]
Hence, ADAMTS13 is an essential protease required
for proteolysis of VWF and the maintenance of normal
hemostasis. A deficiency in ADAMTS13 is observed in
patients with TTP, either due to a congenital defect
resulting in decreased or absent activity, or due to the
presence of autoantibodies inhibiting the activity or
increasing the clearance of ADAMTS13.
Congenital TTP
The congenital form of TTP is caused by mutations
in the ADAMTS13 gene, which is present on chromo-
some 9q34.[14] Congenital or hereditary TTP is also
known as the Upshaw–Schulman syndrome and has
a prevalence of less than 1 case per million per year
and accounts for 2–4% of all TTP cases.[15] The
prevalence of congenital TTP is probably underesti-
mated due to the heterogeneity of the clinical
course and symptoms common to other diseases.
[16]. The autosomal recessive inheritance pattern of
ADAMTS13 mutations was unraveled in 2001 by link-
age analysis in four pedigrees.[14] Heterozygous
mutations result in a reduced ADAMTS13 activity
(40–70%) and a normal phenotype, while TTP symp-
toms are present in over 90% of individuals with
compound heterozygous or homozygous mutations.
[17] Over 140 mutations have been found
distributed throughout the ADAMTS13 gene in more
than 150 patients.[18] More than half of ADAMTS13
mutations are single amino acid substitutions,
whereas the rest include frame-shifts, splice-site
mutations, and nonsense mutations.[18] Most muta-
tions cause secretion defects; however, truncated
forms of ADAMTS13 with decreased enzymatic activ-
ity and/or substrate binding have been reported.[19]
Furthermore, combinations of mutations and single
nucleotide polymorphisms (SNPs) may result in a
more severe ADAMTS13 deficiency.[20] It has been
hypothesized that specific SNPs and ADAMTS13
mutations are typical for specific ethnic sub-
groups.[17]
Often a distinction is made between early- and
late-onset congenital TTP, depending on the patient’s
age at which the first TTP symptoms occur. Early-
onset TTP is characterized by repeated episodes of
thrombocytopenia and hemolytic anemia during
childhood, which is easily detected by neonatal
Coombs-negative jaundice. In contrast, late-onset
TTP, appearing only in adults, is not well character-
ized because of its highly variable clinical onset.[21] It
was suggested that certain ADAMTS13 mutations can
indicate the time of TTP presentation. For example,
the mutation R1060W was initially found in 10
patients with adult-onset TTP only.[22] However, a
child was then identified with the same mutation.
[22] This same mutation was found in a higher than
D T1 C S T2 T3 T4 T5 T6 T7 T8 CUB1 CUB2
100% (n=15)[9]
100% (n=24)[11]
14% (n=7)[9]
17% (n=48)[10]
28% (n=24)[11]
36% (n=67)[12]
28% (n=92)[13]
0% (n=15)[9]
0% (n=15)[9]
35% (n=48)[10]
64% (n=24)[11]
31% (n=67)[12]
31% (n=92)[13]
56% (n=24)[11]
12% (n=67)[12]
46% (n=67)[12]
100% (n=48)[10]
97% (n=67)[12]
97% (n=92)[13]
Figure 1. Epitope mapping of anti-ADAMTS13 autoantibodies demonstrated that almost all acquired TTP patients have anti-spacer
domain antibodies. Anti-ADAMTS13 autoantibodies in plasma from acquired TTP patients were epitope mapped against the
different domains of ADAMTS13: metalloprotease (M) and disintegrin-like (D) domain, a thrombospondin type-1 repeat (T1), a
cysteine-rich (C) and spacer (S) domain, seven additional thrombospondin type-1 repeats (T2–T8) and two CUB domains (CUB1-2).
The percentage of antibodies binding to the specific domain with the corresponding number of patients included in the study is
given in the figure.[9–13]
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expected proportion of patients suffering from preg-
nancy-onset TTP, and might thus be a risk factor
during pregnancy.[23,24] Additionally, suggestions
have been made that the position of the mutation
in ADAMTS13 can be linked to disease severity. It was
suggested that different mutations in the proximal
metalloprotease domain and distal thrombospondin
repeats are associated with a less-aggressive
phenotype in childhood TTP, compared to neonatal
TTP presentation, which is associated with mutations
located in the first proximal thrombospondin domain.
[22] However, siblings with the same ADAMTS13
mutations but different clinical course have been
reported,[25] emphasizing the difficult and unpredict-
able nature of TTP.
Long-term follow-up data of TTP patients are scarce,
hampering our understanding of the impact of single or
multiple TTP attacks on overall quality of life. An Arab
family, with two compound heterozygote family
members having severe early-onset Upshaw–Schulman
syndrome, has been under the longest observation
(44 years) ever.[26] The main long-term symptoms
reported are deep psychological problems and short-
term memory loss, with an enormous impact on daily
life. More understanding of the long-term effects of TTP
is essential and centralized data registries with long-
term patient follow-up are necessary to acquire this
information. International registries are making
attempts to unify and centralize all congenital TTP
patients. The main goal is to obtain insight into this
rare disease, eventually leading to improved health care
by constructing evidence-based guidelines.[27] In 2006,
the International Hereditary TTP registry (www.ttpregis
try.net; ClinicalTrial.gov identifier: NCT01257269) was
established, which in the meantime contains 145
patients and family members from 16 nationalities.
Broader registries exist, including also patients with
acquired TTP or other thrombotic microangiopathies
such as hemolytic uremic syndrome. The United
Kingdom TTP (UK TTP) registry is actively recruiting
patients until 2018 (http://public.ukcrn.org.uk/search/
StudyDetail.aspx?StudyID=8435). Also in other countries
such as Italy (www.ttpdatabase.org), France (www.cnr-
mat.fr), Japan [28], and Australia (https://ttp.registry.org.
au/) patients are being, or have been, recruited.
Despite abundant case reports and research on sev-
eral mutations, many aspects of TTP still remain
unknown. The trigger for an acute episode, the differ-
ent recurrence rates as well as the long-term conse-
quences of TTP, correlated to specific ADAMTS13
mutations, are important aspects that will hopefully
be unraveled by the data gathered within the different
registries.
Acquired TTP
Acquired TTP is characterized by a heterogeneous and
polyclonal autoimmune response against ADAMTS13.
[29] The antibody repertoire of acquired TTP patients
consists of autoantibodies that interfere with the pro-
teolytic activity of ADAMTS13, or increase its clearance
from the circulation.[29,30] Remarkably, approximately
5% of healthy individuals also possess low-affinity and
non-neutralizing anti-ADAMTS13 autoantibodies.[31]
The exact mechanisms of developing an autoimmune
response against ADAMTS13 are still poorly under-
stood. Although acquired TTP is mainly thought to be
a B-cell-mediated autoimmune disease, evidence for a
significant involvement of T-cells is increasing.[32] In
this respect, HLA DRB1*11 was identified as being a
risk factor for the development of TTP as a result of
molecular mimicry.[33] An HLA-DRB1*11-presented
CUB2-derived peptide (FINVAPHAR) demonstrated
substantial homology with peptide sequences derived
from different bacterial proteins.[33,34] It was
suggested that an infection, resulting in the presenta-
tion by antigen-presenting cells of pathogen-derived
peptides that share homology with the CUB2-derived
peptide, might activate an autoimmune response
against ADAMTS13.[33,34]
Epitope mapping and (sub)class distribution of
autoantibodies
The anti-ADAMTS13 autoantibodies present in the
plasma of acquired TTP patients have been intensively
investigated in terms of antibody titer, ADAMTS13
domain specificity, and Ig (sub)class distribution to
unravel a possible link between these parameters and
the severity of the disease. Interestingly, almost all
acquired TTP patients (85–100%) have autoantibodies
against the cysteine/spacer domain of ADAMTS13,
although autoantibodies against the other proximal
domains (MDT) have also been identified (Figure 1).
[9–13,35] In addition, in 14–61% of these patients,
besides the anti-MDTCS autoantibodies, autoantibo-
dies against the distal thrombospondin and CUB
domains were found, illustrating the heterogeneous
anti-ADAMTS13 immune response (Figure 1).[9–13,35]
Anti-ADAMTS13 autoantibodies have been identified
that (partially) neutralize ADAMTS13 activity, thereby
providing an explanation for the observed ADAMTS13
deficiency in these patients.[9,13] All these neutraliz-
ing autoantibodies have an epitope in the ADAMTS13
spacer domain, a domain known to contain the major
exosite for the binding of ADAMTS13 to the unfolded
VWF A2 domain.[9,13] Neutralizing anti-ADAMTS13
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autoantibodies against other functional important
ADAMTS13 domains like the metalloprotease and
CUB domains have not been identified yet. Recently
however, it was reported that autoantibodies directed
against the distal ADAMTS13 domains induce
ADAMTS13 deficiency predominantly by clearing the
enzyme instead of neutralizing its activity.[13,36]
Levels of antibody titers seem to be correlated with
disease severity. Indeed, a high inhibitory titer at the
presentation of acute symptoms is associated with
the persistence of an undetectable ADAMTS13 activity
in remission, leading to a three times higher probabil-
ity of recurrence.[37–39] Moreover, an ADAMTS13
inhibitor titer of 2 or more Bethesda units/mL is asso-
ciated with a lower survival in patients with an
ADAMTS13 activity of <10%.[40] Furthermore, low
ADAMTS13 antigen levels (<13.5 ng/mL) at presenta-
tion are associated with a higher mortality risk.[13]
Also, the isotype distribution of anti-ADAMTS13 auto-
antibodies is a possible prognostic factor for disease
progression. IgGs were found in all patients, with IgG4
(69–90%) as the most prevalent, followed by IgG1
(73–52%), IgG2 (15–50%), and IgG3 (8–33%), as well
as IgM (7–10%) and IgA (19–21%).[12,30] High levels
of IgG4 could suggestively be explained by chronic
antigen stimulation.[41] Patients with high levels of
IgG4 and undetectable levels of IgG1 seem to have an
increased relapsing rate compared to patients with
low IgG4 and detectable IgG1.[30] Additionally, during
the acute phase, a high IgA titer is associated with a
lower platelet count, while a high IgG titer seems to
correlate with the requirement of a higher number of
plasma exchanges (PEXs) to achieve remission.[39,42]
However, large patient studies are needed to identify
strong prognostic factors for disease severity and
relapse.
Pathological consequences of circulating immune
complexes
Antibody binding to ADAMTS13 results in the formation
of circulating immune complexes. In patients with
acquired TTP, immune complexes were indeed
detected during both the acute event and remission.
[43,44] Whereas free anti-ADAMTS13 antibodies were
mainly IgG1 and IgG4 subclasses,[30] anti-ADAMTS13
antibodies present in immune complexes were predo-
minantly of the IgG4 subclass. Ninety-two per cent of
the immune complexes during acute and remission
phase consisted of IgG4 anti-ADAMTS13 antibodies, in
line with the high prevalence of IgG4 anti-ADAMTS13
autoantibodies in the plasma of acquired TTP
patients.[43]
IgM-complexes can form large aggregates with their
corresponding antigens and can easily activate comple-
ment via the classical pathway.[45] IgG-complexes are
usually smaller in size; IgG3 gives the highest comple-
ment activation via the classical pathway, followed by
IgG1 and IgG2, whereas IgG4 is not able to activate
complement and furthermore has a low affinity for
cellular Fc-receptors.[46] IgA-complexes do not activate
complement via the classical pathway, but can initiate
activation via the alternative pathway, which is not
dependent on activation by immune complexes.[47]
IgG4, the main antibody subclass found in TTP patients,
is expected to form small immune complexes with
ADAMTS13 as IgG4 antibodies are involved in the half-
antibody exchange reaction, resulting in random com-
binations of half-antibody fragments that are monova-
lent for a specific antigen.[48] As these small complexes
are not efficiently cleared by the reticulo-endothelial
system or via Fc-receptors, it was suggested that this
might contribute to a longer circulating half-life and
therefore an increased detection level.[43] It remains
however unclear whether these IgG4 complexes, or
complexes with antibodies from another (sub)class,
are able to activate complement or form immune com-
plex deposits in the vascular wall. Nevertheless, com-
plement activation is reported during acute TTP
episodes. Increased levels of complement factors C3a,
C5a, C5b-9, and Bb are detected during the acute phase
of the disease compared to patients in remission,
[49–51] and decrease during PEX treatment.[49]
However, this increase in complement activation mar-
kers is significantly lower compared to the highly ele-
vated markers measured in patients with hemolytic
uremic syndrome.[50] In renal tissue from TTP patients,
C3 and C5b-9 deposition was observed in and around
glomerular endothelial capillaries and within thrombi.
Additionally, C3 deposition was demonstrated in the
glomeruli and tubuli of kidneys from mice suffering
from TTP after exposure to Shigatoxin.[52] It however
remains to be investigated whether immune complexes
are responsible for the increased complement activa-
tion and what role immune complexes play in the
pathophysiology of TTP (Figure 2).
Cloning of autoantibodies to unravel the
pathophysiology of acquired TTP
The predominant isotype of autoantibodies (either
unbound, or circulating in an immune complex) was
demonstrated to contain possible predictive evidence
on the progress of acquired TTP episodes. However, at
present, a fundamental understanding of how exactly
different isotypes influence the pathophysiology of
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acquired TTP is still largely lacking. Epitope mapping of
autoantibodies might provide additional new insights
into the pathophysiology of acquired TTP although it
remains difficult to characterize the effect of a single
antibody in a patient’s antibody repertoire on
ADAMTS13 function, with such a heterogeneous and
polyclonal immune response. Recent advances in the
cloning of autoantibodies, however, open new possibi-
lities to characterize in detail anti-ADAMTS13 antibodies
and to gain more insight into the pathophysiology of
acquired TTP.
Luken et al. were the first to clone anti-ADAMTS13
autoantibodies from mononuclear cells of an acquired
TTP patient in remission.[53] Using phage display, sin-
gle-chain variable (scFv) fragments were expressed as
combined variable heavy (VH) and variable light seg-
ments and were selected against the cysteine/spacer
domain. Seven scFv fragments were identified and
divided into four groups based on their VH germline
gene segments: VH1-69, VH1-01, VH3-09, and VH3-07.
All these different germlines produced anti-cysteine/
spacer antibodies, demonstrating that multiple B-cell
clones develop antibodies against the same domain.
The scFv fragments and full-length IgGs were able to
partially inhibit ADAMTS13 activity, indicating that one
single inhibitory antibody against the spacer domain
might not be enough to explain the pathogenicity of
autoantibodies. Competition experiments performed
with one of the scFv furthermore indicated that anti-
bodies with a similar epitope are present in the plasma
of other acquired TTP patients.[53] The same technique
was used to clone over 130 unique anti-ADAMTS13
antibodies from the immune repertoire of four unre-
lated acquired TTP patients.[54] In the cloned antibody
libraries of both studies, it was observed that the major-
ity of antibodies were derived from the VH1-69 germ-
line and that almost all were able to inhibit the
proteolytic activity of ADAMTS13.[54,55] Recently,
three additional scFv fragments with high affinity,
high inhibitory capacity, and spacer domain specificity
were selected through phage display.[56] With these
scFv fragments, it was demonstrated that antibody
binding to the five loops within the spacer domain,
which is necessary for the correct binding of
ADAMTS13 to VWF, inhibits the proteolysis of VWF by
physical blockage of the ADAMTS13-VWF interaction,
[56] thereby confirming and extending previous pub-
lications.[53,55] Also spleens of acquired TTP patients
were found to be a rich source of antibody-producing
cells. The group of Kremer-Hovinga was able to isolate
29 clones from spleens of two acquired TTP patients
through phage display and Epstein Barr Virus transfor-
mation.[57] Of these antibodies, 93% were inhibitory
and 79% were directed against the spacer domain.
Only a limited amount of VH genes were found: VH1-
3, VH1-69, VH3-30, and VH4-28, as well as a limited
number of CDR3 motifs, of which four were shared by
the two patients.[57] These recent developments have
demonstrated that the spleen contains a limited auto-
immune repertoire against ADAMTS13. Most cloned
autoantibodies share common CDR3 motifs, inhibit
ADAMTS13 activity, and are directed against the spacer
Immune complex deposition?
Complement 
activation?
 Neutrophil
activation?
NET release
 ElastaseUL-VWF
Platelet
(Anti-)ADAMTS13
immune complex
Plasmin
Plasmin 
activation?
uPA/uPAR
VWF 
proteolysis?
NETs in 
thrombi?
VWF-rich
microthrombus
Figure 2. Other processes with a possible role in TTP: immune complexes, activated neutrophils, and plasmin. Circulating immune
complexes of anti-ADAMTS13 autoantibodies bound to ADAMTS13 have been demonstrated in plasma from TTP patients. Whether
these immune complexes are deposited in underlying tissues or activate complement, and subsequently play a role in the
underlying pathophysiology is currently not known. Additionally, possible activation of neutrophils during acute TTP episodes
has been demonstrated by the presence of elevated plasma levels of neutrophil extracellular traps (NET) markers and neutrophil
elastase. Elevated NET markers indicate a possible role of NETs in the progression of TTP symptoms, as NETs have the ability to bind
platelets and promote thrombus formation. Elastase on the other hand is able to cleave VWF in vitro and could support the
degradation of UL-VWF multimers. Also plasmin has the capacity to proteolyze VWF, when activated via the uPA/uPAR pathway.
Elevated plasmin levels were demonstrated during the acute phase of TTP and could play a role in the size modulation of VWF.
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domain. As the pathogenic relevance of shared CDR3
motives was demonstrated in other autoimmune dis-
eases such as chronic lymphocytic leukemia,[58] shared
CDR3 motifs might also be crucial for the pathogenicity
of anti-ADAMTS13 autoantibodies. Characterization of
novel cloned autoantibodies will provide us with more
information on the polyclonal immune response in
acquired TTP patients. In addition, it would especially
be interesting to unravel whether acquired TTP patients
have anti-distal autoantibodies that inhibit ADAMTS13
function given the functional role of distal domains in
the docking of ADAMST13 to VWF. On the other hand,
such autoantibodies might not be present in acquired
TTP patients as it was recently described that autoanti-
bodies directed against the distal domain are mainly
clearance-inducing autoantibodies.[13] Future studies
will definitely help us better understand the role of
the immune system, and more specifically the role of
B- and T-cells, in the formation of autoantibodies.
Current and future treatment opportunities for
TTP
Acute TTP episodes require prompt treatment. For
more than 20 years, the use of PEX or plasma infusion
has been crucial in the management of TTP episodes,
reducing mortality rates from 90% to 10–20%.[59,60]
PEX is superior to plasma infusion for acquired TTP
and should be initiated once a presumptive diagnosis
of TTP is made.[59] PEX not only replaces the deficient
or inhibited ADAMTS13 by active ADAMTS13 from
donor plasma, but also removes potential disease-caus-
ing factors such as autoantibodies, immune complexes,
or bacterial toxins from the circulation. Plasma infusion
only replenishes ADAMTS13 activity in acquired TTP
patient’s plasma and can provide temporary benefit
until PEX can be initiated.[61] The number of PEX
required to achieve remission depends on the severity
of initial disease or progression of the symptoms during
admission. In general, patients with acquired TTP
require a higher number of PEX and longer treatment
to normalize platelet counts compared to congenital
TTP patients. Due to the lack of circulating antibodies
in patients with congenital TTP, regular plasma infu-
sions alone are generally sufficient to achieve remission
or prevent TTP relapses. In patients with acquired TTP,
immunosuppressive drugs are used as adjuvant therapy
to PEX. Immunosuppressive agents tone down
the immune response and suppress the production of
new autoantibodies. Consistent use of corticosteroids in
addition to PEX seems to further increase survival and
reduce the frequency of relapses, especially in patients
with severe acquired ADAMTS13 deficiency.[62]
Recently, rituximab, a humanized anti-CD20 monoclo-
nal antibody, has been shown to be a safe and effective
adjunct to PEX, especially in patients with refractory or
relapsing TTP.[62] Standard intravenous rituximab treat-
ment (375 mg/m2 weekly for 4 weeks) results in B-cell
depletion, reduced anti-ADAMTS13 antibody titers, and
increased plasma ADAMTS13 activity in most patients.
[62] Early administration, preferably within the first 3
days, is associated with faster attainment of remission,
fewer number of PEX, shorter hospitalization, and a
reduced relapsing risk.[63] These benefits have stimu-
lated the use of rituximab as prophylactic therapy in
patients with a history of TTP and deficient ADAMTS13
activity in remission.[64] Although preventive rituximab
infusions maintained a sustained remission in these
patients,[64] concerns regarding overtreatment and
increased susceptibility for infections are raised and
therefore a risk/benefit ratio on an individual patient
level has yet to be made.
Since the introduction of PEX in clinical practice,
survival rates did not further increase during the last
20 years. However, due to a better insight into the
pathophysiology of TTP, different novel adjuvant treat-
ment strategies have been investigated (Table 1).
Blocking the VWF–GPIb interaction
One novel strategy encompasses the blockade of the
VWF–platelet glycoprotein (GP)Ib interaction, thereby
preventing the formation of VWF-rich platelet thrombi.
ARC1779, an aptamer blocking the GPIb-binding VWF
A1 domain, inhibits the formation of occlusive thrombi
in a carotid artery thrombosis model in cynomolgus
monkeys.[65] This aptamer was the first targeted ther-
apy tested in humans and provided proof of principle
for this approach in the treatment of TTP in a small
cohort of patients.[66] More comprehensive data
regarding the efficacy of inhibiting the VWF–GPIb inter-
action were obtained from other preclinical and clinical
studies. In a baboon model of acquired TTP, the anti-
body GBR600 [67] and the nanobody Caplacizumab,[68]
both targeting the VWF A1 domain, were capable of
treating and preventing TTP symptoms. Caplacizumab
was subsequently tested in a multicenter phase II ran-
domized, placebo-controlled trial, in which acquired
TTP patients were given Caplacizumab as an adjunct
to daily PEX.[69] Caplacizumab-treated patients
achieved faster platelet normalization and developed
less recurrent thrombocytopenia that required initiation
of PEX <30 days after the last PEX therapy.[70]
Interestingly, only minor bleeding episodes and man-
ageable side effects were observed in patients in the
active drug treatment arm. These data suggest that by
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preventing the interaction between VWF and platelets,
the standard of care of TTP patients might improve.
rADAMTS13
Another potential future therapy is the use of recombi-
nant ADAMTS13 (rADAMTS13) as substitute for human
plasma. Preclinical animal studies have demonstrated
that the administration of rADAMTS13 before or after
induction of TTP in Adamts13-/- mice reduced the inci-
dence of severe thrombocytopenia and organ damage.
[71] A phase I clinical trial was recently initiated to
assess rADAMTS13 in the treatment and prophylaxis
of congenital TTP. Although the approach indeed
seems more applicable to congenital TTP patients, in
vitro studies nevertheless have shown that rADAMTS13
is able to restore ADAMTS13 activity in the plasma of
acquired TTP patients.[82] This was confirmed in an in
vivo rat model of acquired TTP. Following the adminis-
tration of anti-ADAMTS13 antibodies, infusion of
rADAMTS13 did override the effect of the inhibitory
antibodies, resulting in the reduction of severe TTP
symptoms such as thrombocytopenia and hemolytic
anemia, demonstrating promising value for future treat-
ment also in acquired TTP.[72] An elegant way to cir-
cumvent autoantibody inhibition of rADAMTS13 may
be the administration of autoantibody-resistant
ADAMTS13 variants. Jian and colleagues have demon-
strated that, by modifying an exosite in the spacer
domain of ADAMTS13, binding of autoantibodies to
these ADAMTS13 variants was reduced while the VWF-
cleaving activity was preserved or even enhanced.[73]
Furthermore, transgene expression of ADAMTS13 from
platelets has recently been shown to prevent both
congenital and acquired TTP in mice.[74] Despite the
fact that translation into clinic is challenging, this
approach is promising as the platelet-derived
rADAMTS13 is less susceptible to inhibition by inhibi-
tory anti-ADAMTS13 antibodies.
Reducing the size of VWF multimers
Recently, Chen and colleagues demonstrated that VWF
multimer size can be pharmacologically decreased with
N-acetylcysteine (NAC).[75] Although this FDA-
approved drug is currently used to treat acetamino-
phen toxicity and chronic obstructive lung disease, it
has been shown that NAC can reduce intrachain dis-
ulfide bonds, thereby reducing circulating UL-VWF mul-
timers in the plasma of mice.[75] Hence, NAC could
reduce the size of UL-VWF multimers in TTP patients.
Human case reports on TTP treatment with NAC how-
ever demonstrated varying outcomes [83–85] and a
clinical trial is currently ongoing to test its efficacy
under controlled conditions. Finally, activation of plas-
minogen using thrombolytic agents could be a possible
new treatment strategy. Plasmin was shown to cleave
VWF, resulting in a reduction of TTP symptoms in a
mouse model of congenital TTP.[76]
Table 1. New treatment strategies for the treatment of congenital and acquired TTP.
Strategy Drugs Experimental phase Outcome
Blocking VWF-platelet
GPIb interaction
ARC1779 Cynomolgus monkeys [65] Inhibition of formation of occlusive thrombi
Placebo-controlled clinical study
(n = 9) [66]
Supported safety
GBR600 Baboons [67] Prevention and treatment of TTP symptoms
Caplacizumab Baboons [68] Prevention and treatment of TTP symptoms
Phase II placebo-controlled clinical
trial [69,70]
Faster platelet normalization, less recurrent
thrombocytopenia
Replenish ADAMTS13
activity by recombinant
enzyme
rADAMTS13 (BAX930) Mouse model for congenital TTP [71] Reduced thrombocytopenia and severe organ damage
Rat model for acquired TTP [72] Overriding inhibitory antibodies, reduction of severe TTP
symptoms
Phase I dose-escalation study Ongoing, assess safety and pharmacokinetics in
congenital TTP patients
Autoantibody-resistant
rADAMTS13
In vitro study [73] Reduced binding of autoantibodies, VWF-cleaving
activity preserved
Platelet-delivered
rADAMTS13
Mouse model for congenital and
acquired TTP [74]
Prevention of TTP symptoms
Reducing VWF
multimer size
N-acetylcysteine Adamts13-/- mice [75] Reduction of circulating UL-VWF multimers, faster
mesenteric thrombus resolution
Pilot clinical study in TTP patients Ongoing, assess platelet count, number of plasma
exchange required and microvascular thrombotic
complications
Thrombolytic agents Mouse model for congenital TTP [76] Activation of plasmin cleaved VWF and reduced TTP
symptoms
Gene therapy Viral vectors Adamts13-/- mice [77–80] Restoration of ADAMTS13 antigen and activity
Mouse model for congenital TTP [80] Prevention of TTP symptoms
Nonviral vectors Mouse model for congenital TTP [81] Reduced thrombocytopenia and severe organ damage
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Gene therapy
Lifelong treatment with plasma products, mainly in
patients with congenital TTP, is inconvenient, expen-
sive, and can result in complications (e.g. fever, urti-
caria). Gene therapy for TTP offers a long-term
treatment that would improve the patient’s comfort
and quality of life. Different gene therapeutic
approaches have already been investigated in mouse
models. Using viral [77–80] and nonviral [81] vectors
that encode full-length ADAMTS13 or the MDTCS frag-
ment, long-term expression of transgene enzyme in
Adamts13-/- mice was achieved and resulted in the
elimination of circulating UL-VWF multimers and the
prevention of TTP symptoms after challenge with
shigatoxin [80] or recombinant human VWF.[81]
Although more research is needed to progress from
preclinical phase to clinical trial, recent advances in
gene therapy for other monogenetic disorders such as
hemophilia B [86] and X-linked severe combined immu-
nodeficiency [87] are encouraging to further develop
gene therapy for the treatment of congenital TTP
patients.
Other proteases beyond ADAMTS13 in TTP
pathology
ADAMTS13 levels do not always predict TTP occur-
rence. Patients with undetectable ADAMTS13 levels
can remain asymptomatic for years, which have led
to the concept of a triggering event that induces the
onset of acute TTP symptoms. Alternatively, in the
absence of ADAMTS13 it is possible that other pro-
teases might help regulate VWF size and hence con-
tribute to the pathophysiology of TTP. A variety of
enzymes, such as plasmin, thrombin, and different
leukocyte proteases, can cleave VWF in vitro [88,89].
Whereas thrombin has a relatively weak capacity to
cleave VWF,[88] leukocyte proteases and plasmin on
the other hand seem to play a more important role in
VWF size regulation in vitro.
Leukocytes
Leukocyte proteases secreted by mainly neutrophils
including PMNE, proteinase 3 (PR3), cathepsin G, and
matrix metalloprotease 9 (MMP-9) are all able to pro-
teolyse VWF.[89] By performing mass spectrometry on
cleaved FRETS-VWF73 substrate, it was demonstrated
that cathepsin G has the same cleavage site as
ADAMTS13 (Tyr1605-Met1606), whereas MMP-9 cleaves
one amino acid distal from this cleavage site (Met1606-
Val1607) and PMNE and PR3 two amino acids distal
(Val1607-Thr1608).[89] This suggests that neutrophils
trapped in VWF-rich microthrombi during acute TTP
episodes might be able to modulate the cleavage of
VWF in the absence of ADAMTS13 (Figure 2). However,
evidence that this might be the case is still largely
lacking and recent studies on neutrophil-derived NETs
actually suggest a role of neutrophils in TTP pathology.
NETs are extracellular DNA traps released from neutro-
phils that undergo ‘netosis’ and have recently been
shown to promote thrombus formation.[90]
Interestingly, during acute TTP episodes, increased
amounts of NET markers such as extracellular DNA
and histones are observed in patient plasma and even
correlate with disease activity.[91] In addition, TTP
patients were shown to have decreased levels of
DNaseI, which could impair NET degradation.[92] This
suggestively implies that NET formation is either trig-
gered by acute episodes of TTP, or plays a role in the
onset of acute symptoms (Figure 2). Clearly, further
studies are needed to elucidate the role of neutrophils,
the release of leukocyte proteases, and the formation of
NETs in TTP.
Plasmin
Next to leukocyte proteases, plasmin also has the
ability to degrade VWF.[76,88,93] The exact cleavage
site(s) within VWF are yet unknown; however, a
lysine-dependent binding of plasminogen to the
VWF A1 domain has been demonstrated.[76] The
zymogen plasminogen circulates in the plasma, and
can be activated by tissue plasminogen activator
(tPA) or urokinase plasminogen activator (uPA) into
plasmin. In vitro cleavage of VWF by plasmin was
demonstrated to be dependent on uPA and its recep-
tor (uPAR) for plasminogen activation and subse-
quent proteolytic activity (Figure 2).[76] Plasmin
activity is tightly regulated by several inhibitors.
Plasminogen activator inhibitor-1 (PAI-1) is the main
inhibitor of uPA and tPA, whereas α2-antiplasmin and
α2-macroglobulin directly inhibit active plasmin. The
role of the plasminogen activation system in TTP is
still unclear, but several reports indicated a possible
role in TTP pathology. Elevated plasmin-α2-antiplas-
min complexes, indicative for increased plasmin activ-
ity, have been found in plasma samples from patients
with acute TTP (Figure 2).[76] Furthermore, increased
uPAR-expression was demonstrated in kidney biop-
sies of patients with TTP.[94] This indicates that acti-
vation of several components of the plasminogen
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activation pathway occurs during the acute phase of
TTP. However, despite the higher plasmin activity,
patients still develop TTP symptoms. One explanation
for this might be an increased inhibition of plasmin,
as elevated PAI-1 levels have been measured during
the acute phase of TTP compared to patients in
remission.[95]
However, it remains unclear whether plasmin acti-
vation might not also aggravate acute TTP, as plas-
min also has the ability to cleave ADAMTS13, thereby
reducing its activity.[96] Not only plasmin, but also
thrombin and factor Xa were able to cleave
ADAMTS13 into non-active fragments. Indeed, in a
patient with acute TTP, ADAMTS13 was found to be
proteolytically degraded by plasmin.[97] It was there-
fore suggested that cleavage of ADAMTS13 by plas-
min was the cause of TTP in this patient. Therefore,
plasmin might regulate TTP episodes or contribute to
the onset of TTP by either cleaving VWF or cleaving
plasma ADAMTS13, respectively. However, the exact
contribution of both pathways in the development of
TTP remains to be determined.
Discussion and conclusion
With the trigger for disease onset or autoantibody
formation still unknown, the etiology around TTP is
still not clear. TTP registries in different countries
made it possible to unify patient data, aiming to
increase the number of patients available to obtain
more insights into this rare disease. Research is
currently focusing on the formation of autoantibo-
dies, demonstrating that cloned autoantibodies
can provide us with more information on the func-
tional aspects of the antibodies and more informa-
tion on the autoimmune repertoire. New therapeutic
strategies for the treatment of congenital or
acquired TTP currently in clinical trials include the
anti-VWF A1 domain nanobody Caplacizumab and
recombinant ADAMTS13. These new strategies hold
promising value for future treatment of this severe
disease.
Expert commentary
Many efforts have been made to link antibody titer,
ADAMTS13 domain specificity, and Ig (sub)class dis-
tribution of anti-ADAMTS13 autoantibodies with dis-
ease severity and relapse. A better understanding of
the role of anti-ADAMTS13 autoantibodies in the
pathophysiology TTP together with larger patient stu-
dies is however required to provide physicians with
strong prognostic factors that are helpful in disease
management. It is furthermore very important to seek
for new treatment strategies, as TTP patients suffer
from devastating symptoms and not always respond
to PEX treatment or rituximab. Current new
developments regarding TTP treatment hold promis-
ing value for future therapy. With Caplacizumab and
rADAMTS13 in clinical trials, better and safer treat-
ment strategies supplementing or completely repla-
cing current PEX are coming closer toward clinical
use. The value of new experimental drugs and stra-
tegies such as autoantibody-resistant ADAMTS13,
NAC, plasmin, and (non-)viral gene therapy still have
to demonstrate their potential in more appropriate
animal models or in clinical trials. However, we
believe that within a few years, better and safer
treatment strategies will be available for this severe
and life-threatening disease.
Five-year view
We believe that within the next five years, different
congenital TTP registries will combine their data to
increase the patient population. With a larger number
of patients, it will be easier to find the trigger for
acute episodes, indications for recurrence of acute
episodes, and long-term consequences of TTP. We
furthermore think that in the coming years, the role
of anti-ADAMTS13 autoantibodies in the pathophy-
siology of acquired TTP will be unraveled. Cloning
of autoantibodies is currently ongoing in several
research groups and will further unravel the complete
autoantibody repertoire in acquired TTP patients. For
both congenital as well as acquired TTP, strong prog-
nostic factors to predict disease severity and relapse
are expected to be established in the coming years.
And last, better treatment opportunities will be avail-
able soon once proven successful in current ongoing
clinical trials.
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